NewAmsterdam Pharma (NASDAQ:NAMS) Director John Smither Sells 1,600 Shares

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director John Smither sold 1,600 shares of NewAmsterdam Pharma stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $25.32, for a total value of $40,512.00. Following the completion of the transaction, the director directly owned 8,760 shares in the company, valued at $221,803.20. This represents a 15.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

NewAmsterdam Pharma Trading Down 11.1%

NAMS stock opened at $22.79 on Thursday. NewAmsterdam Pharma Company N.V. has a one year low of $22.34 and a one year high of $42.21. The firm has a market capitalization of $2.72 billion, a PE ratio of -10.55 and a beta of 0.09. The firm has a 50-day moving average of $29.10 and a two-hundred day moving average of $31.37.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its earnings results on Wednesday, August 5th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%.The firm had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $2.83 million. On average, equities research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.82 earnings per share for the current year.

Key Stories Impacting NewAmsterdam Pharma

Here are the key news stories impacting NewAmsterdam Pharma this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating on NewAmsterdam Pharma and maintained a $52 price target, implying substantial upside from recent trading levels. The bullish view supports the long-term investment case, although it has not prevented near-term selling pressure. Benzinga analyst rating report
• Neutral Sentiment: Recent analyst coverage discussed NewAmsterdam Pharma alongside other healthcare companies, including Dyne Therapeutics, Ionis Pharmaceuticals and Amgen. The reports may influence sector positioning, but the available headlines do not identify a new company-specific development for NAMS. Analyst insights on healthcare companies Analyst insights on Amgen and NewAmsterdam Pharma
• Negative Sentiment: Director John W. Smither sold 1,600 NAMS shares for approximately $40,512, reducing his position by 15.44%. While insider sales can be made for personal or financial reasons, the transaction may add to investor caution when the stock is already under pressure. SEC insider transaction filing
• Negative Sentiment: A sharp trial-related selloff in Novartis and resulting weakness in other biotechnology stocks has likely hurt sentiment toward the broader drug-development sector. The read-through is indirect for NAMS, but it may encourage investors to reduce risk across biotech holdings. Novartis trial-failure market impact

Analysts Set New Price Targets

NAMS has been the subject of a number of research analyst reports. Royal Bank Of Canada reduced their target price on NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Jefferies Financial Group reissued a “buy” rating and set a $45.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Friday, July 17th. HC Wainwright reiterated a “buy” rating and issued a $52.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday. Finally, BMO Capital Markets started coverage on shares of NewAmsterdam Pharma in a report on Monday, July 20th. They set an “outperform” rating and a $58.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $49.73.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN grew its position in NewAmsterdam Pharma by 50.0% in the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after acquiring an additional 300 shares in the last quarter. KBC Group NV bought a new position in shares of NewAmsterdam Pharma during the 1st quarter valued at $37,000. Navalign LLC acquired a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at $46,000. AdvisorNet Financial Inc bought a new stake in NewAmsterdam Pharma in the first quarter worth $82,000. Finally, Empowered Funds LLC bought a new stake in NewAmsterdam Pharma in the fourth quarter worth $85,000. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical?stage biopharmaceutical company focused on discovering and developing novel small?molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small?molecule candidates at various stages of preclinical and clinical evaluation.